Articles from Light Chain Bioscience

Light Chain Bioscience, a clinical-stage biotechnology company advancing the next generation of bispecific antibodies to treat cancer, today presented updated long-term results from a Phase 1/1b study of NI-1801 as a monotherapy and in combination with pembrolizumab in heavily pretreated Platinum Resistant Ovarian Cancer (PROC) patients that have no approved standard of care treatment. The data were reported in a Poster presentation at European Society of Medical Oncology (ESMO) Congress in Madrid.

Light Chain Bioscience, a clinical-stage biotechnology company advancing the next generation of bispecific antibodies to treat cancer, today presented positive results from a Phase 1/1b study of NI-1801 as a monotherapy and in combination with pembrolizumab in heavily pretreated Platinum Resistant Ovarian Cancer (PROC) patients. The results were reported in a Proffered Paper oral presentation at the 2025 European Society of Medical Oncology (ESMO) Congress in Berlin.